MindBio Therapeutics Reports Improvement in Depression Trial Outcomes

Vancouver, June 12, 2024 – MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), a biopharmaceutical company specializing in psychiatric medicines, has announced positive secondary data from its Phase 2A depression trial using MB22001. The trial, conducted earlier this year, focused on the take-home microdosing of psychedelic medicines.

The data revealed notable improvements in secondary outcomes after an 8-week treatment with MB22001, including a 52% reduction in anxiety (HAM-A) and significant decreases in stress (35%), anxiety (59%), and depression (40%) based on the DASS questionnaire. Furthermore, there was a 37% improvement in participants' psychological quality of life as measured by WHOQOL.

Previous data showed a 60% decrease in depressive symptoms according to the MADRS score and a 53% rate of complete remission. The company is currently assessing the long-term antidepressant effects of MB22001.

Safety analysis indicated a favorable profile with low adverse event frequency. No serious or severe events were reported, and no significant abnormalities were detected in follow-up tests.